Next-generation cloud application enables study build in as little as
7 weeks
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE:VEEV) today announced that leading pharmaceutical
companies and CROs are now using Veeva
Vault EDC to improve data management in their clinical trials. Vault
EDC provides a modern, flexible EDC solution to build studies faster and
more effectively run trials. In just over a year since the product’s
availability, 12 early adopters have initiated studies with Vault EDC,
including a top 20 global pharmaceutical company. Multiple studies are
already live and using Vault EDC across a wide range of therapeutic
areas, including oncology, ophthalmology, medical device, and
cardiovascular.
“The ability to effectively manage clinical data is essential as trials
become more complex,” said Alison Liddy, SVP clinical risk and data
management at ICON, who is running a trial on behalf of a customer
leveraging Veeva Vault EDC. “Veeva Vault EDC gives us a next-generation
EDC to collect patient data easier and with greater flexibility.”
Vault EDC is helping clinical data management teams accelerate their
study design and start trials in as little as seven weeks. Studies are
configured utilizing drag-and-drop tools instead of editing complicated
lines of code, dramatically reducing time to build a study database. The
advanced architecture and easy-to-use, intuitive interface of Vault EDC
also deliver a simplified experience managing study changes without
costly migrations or downtime.
“We recognize the critical importance that EDC system set-up,
maintenance, and flexibility plays in data collection and
decision-making during oncology trials,” said Robert Wittig, president
at Trevie Research who is managing the International
Myeloma Foundation's ASCENT (Aggressive Smoldering Cure Evaluating
Novel Rx Transplant) trial. “Veeva Vault EDC provides a modern, adaptive
EDC cloud application that establishes a new era of innovation in
clinical data management.”
“Veeva is honored to work with leading life sciences companies to
streamline clinical data management and accelerate trial execution,”
said Richard Young, vice president of Veeva Vault EDC. “We’re excited to
bring the industry a modern EDC application that enables greater speed
and agility in clinical trials.”
Vault EDC is part of Veeva
Vault Clinical Suite that combines EDC, CTMS, eTMF, and study
start-up to unify clinical
data management and clinical
operations on a single cloud platform. Veeva’s suite of unified
applications provides teams with global visibility of trial processes
and information. Now organizations can easily manage their entire trial
portfolio and streamline their end-to-end clinical processes.
In other news today, Veeva announced that Tufts
Center for the Study of Drug Development (CSDD) will preview its
study findings on the root causes for delays and inefficiencies
impacting trial timelines as a follow-up to the 2017
eClinical Landscape Study. Read our press
release to learn more and join Veeva and Tufts CSDD at the DIA 2018
Annual Meeting on Tuesday, June 26, at 1:10 p.m. in theater #2 of the
exhibit hall for more details on the study results and their
implications. Richard Young will also share Veeva’s vision for the
future of clinical data management. Learn more at veeva.com/DIA2018.
Also, join the growing Veeva clinical data management community and
learn more about Veeva and its clinical partners at the upcoming Veeva
R&D Summit in Philadelphia, September 16-18.
Additional Information
For more on Veeva Vault EDC, visit: veeva.com/EDC
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About ICON plc
ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to pharmaceutical,
biotechnology, medical device, and government and public health
organisations. The company specializes in the strategic development,
management and analysis of programs that support clinical development
from compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 97
locations in 38 countries and has approximately 13,380 employees. For
more information ICONplc.com.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 625 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2018. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180621005979/en/
Source: Veeva Systems